HEOR & Real-World Evidence
Helping you determine, demonstrate, communicate and realize product value
Important developments are reshaping the landscape for new therapeutic innovations. In the U.S., advances in patient-level data and wider use of comparative effectiveness signal greater expectations for developing evidence of value. In Germany, changes to drug reimbursement (AMNOG) bring a new mandate for demonstrating additional benefit. Globally, the increasing convergence of HTA and regulatory hurdles places health economics and outcomes research at the center of development activities. Underpinning these trends is growing recognition of the need for more and better information.
Our international team of highly qualified, multi-disciplinary specialists in health economics and outcomes research have proven expertise at the global, regional and local level, generating the real-world evidence of value that enables more informed decision making. Leveraging world-class analytics, rigorous methodologies and the most comprehensive patient data assets available, they deliver scientifically sound, commercially focused strategies and dossier submissions, with value arguments tailored to the needs of each individual stakeholder.
- How can we fulfill HTA requirements nationally, regionally and locally?
- What is the economic burden of this disease in the healthcare system?
- What are the patient-reported and other real-world outcomes of our product?
- How does our intervention’s incremental cost compare with its anticipated benefits?
- How can we build a strong value proposition with the right scientific rigor?
HOW WE HELP
- Value strategy development
- Market access planning and strategy
- Health economic modeling and evidence synthesis
- Retrospective outcomes research
- Observational outcomes research
- Value communications
- Risk management, drug safety & epidemiology
A leading pharmaceutical company approached IMS Consulting Group for help in developing health economics support for its novel combination product – a single-pill version of two individual products already available for interrelated but distinct cardiovascular conditions.
A compelling value proposition, based on retrospective analysis and economic modeling, demonstrating the economic advantage of improved compliance with a single pill. This was supported by publication of study results in the Annals of Internal Medicine revealing the unique problem of adherence in patients with dual disease.